SAN DIEGO, March 4, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that its abstract demonstrating the ability of
the Company's Target Selector™ liquid biopsy test to detect
ESR1 mutations with high sensitivity has been accepted for a
poster presentation at the 2019 American Association for Cancer
Research (AACR) Annual Meeting being held March 29-April 3, 2019 at the Georgia World
Congress Center in Atlanta.
"ESR1 mutation testing by means of liquid biopsy affords testing
of a treatment predictive biomarker in patients with hormone
receptor positive metastatic breast cancer, the subtype present in
the majority of patients," said Lee
Schwartzberg, MD, FACP, Executive Director of West Cancer
Center and Professor of Medicine, University of Tennessee Health Science Center.
"This method of testing can offer the promise of monitoring
patients for the emergence of resistance to certain types of
endocrine therapy in a timely manner using a simple blood
sample."
Details for the poster presentations are as follows:
Title: Validation of highly sensitive ctDNA assays
for ESR1 resistance mutations with the NGS Target Selector™
enrichment technology
Session Category/Title: Clinical Research/Current
Developments in Non-invasive Biomarkers for Assessment of Cancer
3
Session Date and Time: Monday, April 1, 2019;
1:00 p.m. - 5:00 p.m. Eastern
time
Location: Georgia World Congress Center, Exhibit Hall
B
"Our poster at the AACR conference, once again, highlights the
performance and versatility of our proprietary liquid biopsy
technology. This year's poster presentation features the expansion
of our high-sensitivity Target Selector™ assay platform to
encompass emerging biomarkers, like ESR1 alterations, which are
being used for the development of new targeted treatments for
breast cancer," said Michael Nall,
President and CEO of Biocept. "We believe the validation
of this assay to detect actionable biomarkers associated with
metastatic breast cancer can provide information to aid in therapy
selection and in monitoring patient response to therapy, as well as
potentially improving patient outcomes."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the platform has
demonstrated the ability to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the potential clinical
utility of our proprietary technology platform and our ability
to broaden the use of our proprietary technology platform, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocepts-liquid-biopsy-test-for-esr1-biomarker-detection-to-be-featured-in-poster-presentation-at-the-2019-aacr-annual-meeting-300804845.html
SOURCE Biocept, Inc.